Non-vitamin K oral antagonist (NOAC) compared to vitamin K antagonist (VKA) in left ventricular thrombus.
Left ventricular thrombus
oral antagonist
vitamin K antagonist
warfarin
Journal
Journal of family medicine and primary care
ISSN: 2249-4863
Titre abrégé: J Family Med Prim Care
Pays: India
ID NLM: 101610082
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
02
12
2023
revised:
18
02
2024
accepted:
18
03
2024
medline:
19
7
2024
pubmed:
19
7
2024
entrez:
19
7
2024
Statut:
ppublish
Résumé
Thromboembolic events are serious left ventricular thrombus (LVT) complications. Despite the limitations of vitamin K antagonist (VKA) drugs, it continues to be the recommended oral anticoagulation for LVT. Recently, nonvitamin K oral antagonist (NOAC) has gained popularity as an off-labeled treatment for systemic embolism prevention in LVT. In this study, we aim to compare the outcomes (stroke and bleeding) of warfarin versus NOAC therapy in patients with LVT. This retrospective cohort study compares NOAC and VKA therapy in LVT patients. We enrolled 201 patients with an echocardiography-confirmed LVT from January 2018 to December 2022. Patients who received NOAC therapy (NOAC, The median follow-up time was 17 months (25 In patients with LVT, NOAC was as effective as VKA in stroke prevention without increasing the risk of major bleeding.
Sections du résumé
Background
UNASSIGNED
Thromboembolic events are serious left ventricular thrombus (LVT) complications. Despite the limitations of vitamin K antagonist (VKA) drugs, it continues to be the recommended oral anticoagulation for LVT. Recently, nonvitamin K oral antagonist (NOAC) has gained popularity as an off-labeled treatment for systemic embolism prevention in LVT.
Objective
UNASSIGNED
In this study, we aim to compare the outcomes (stroke and bleeding) of warfarin versus NOAC therapy in patients with LVT.
Methods
UNASSIGNED
This retrospective cohort study compares NOAC and VKA therapy in LVT patients. We enrolled 201 patients with an echocardiography-confirmed LVT from January 2018 to December 2022. Patients who received NOAC therapy (NOAC,
Results
UNASSIGNED
The median follow-up time was 17 months (25
Conclusion
UNASSIGNED
In patients with LVT, NOAC was as effective as VKA in stroke prevention without increasing the risk of major bleeding.
Identifiants
pubmed: 39027879
doi: 10.4103/jfmpc.jfmpc_1905_23
pii: JFMPC-13-2485
pmc: PMC11254081
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2485-2490Informations de copyright
Copyright: © 2024 Journal of Family Medicine and Primary Care.
Déclaration de conflit d'intérêts
There are no conflicts of interest.